ArticleComputational and structural biotechnology journal2025
Repurposing of the nucleoside analogs for influenza.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond assembly: functions of the coronavirus M protein.Virology journal · 2026Review
- The Redesign of the Molecular Scaffold of Viral Ion Channel Blockers.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza viruses remain a global health concern prompting the search for new antivirals. Drug repurposing offers an efficient approach to identify potential therapeutics. This study repurposed 35 FDA-approved nucleoside analogs, screening them against influenza H1N1. Seven compounds exhibited significant antiviral activity, with cytidine analogs Gemcitabine (IC₅₀ = 0.64 ± 0.21 µM) and 5-Azacytidine (IC₅₀ = 3.42 ± 0.38 µM) showing the strongest inhibition. Molecular dynamics simulations showed that key binding site residues (Arg45, Lys229, Arg239, Lys308, Lys480) and a magnesium ion are crucial for drug binding. Stable hydrogen bonds between active analogs and specific residues (Arg239, Thr307, Asn310), along with significant interactions with RNA complementary bases, are associated with antiviral activity. These findings offer structural insights into polymerase inhibition and provide a foundation for future drug design and monitoring of resistance development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.